MedTrace Logo

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2018-02-23

Study results available
· View outcomes & findings →

Summary

To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy

Conditions

Interventions

DRUG

AEGR-733

3 capsules each evening for each 4-week period

DRUG

placebo

3 capsules each evening for each 4-week period

DRUG

AEGR-733

3 capsules each evening for each 4-week period

DRUG

AEGR-733

3 capsules each evening for each 4-week period

DRUG

AEGR-733

3 capsules each evening for each 4-week period

DRUG

AEGR-733 and atorvastatin

3 capsules each evening for each 4-week period

DRUG

AEGR-733 and fenofibrate

3 capsules each evening for each 4-week period

DRUG

AEGR-733 and ezetimibe

3 capsules each evening for each 4-week period

Sponsors & Collaborators

  • Aegerion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • William Sasiela, PhD · Aegerion Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00559962 on ClinicalTrials.gov